Biosan Biology

China's largest one-stop production and marketing service provider for maternity testing

•Founded in 2003, it is located in Hangzhou, Zhejiang Province. It is the earliest and largest overall solution provider in the domestic birth defect market. 

•Focusing on prenatal screening and diagnosis center, neonatal disease screening center and gynecology and obstetrics department of general hospital to provide in vitro diagnosis in the field of pregnancy and obstetrics medical testing market (birth defect prevention and control).Provide one-stop solutions for in vitro diagnostic instruments, reagents and supporting products and services to domestic maternal and child health institutions at all levels, carry out birth defect screening and diagnosis projects including traditional serological prenatal screening, NIPT non-invasive prenatal screening, and provide third-party medical testing services related to birth defect prevention and control. 

•It provides the leading screening and diagnosis technology for birth defects at home and abroad, including time-resolved fluorescent immune technology, second-generation sequencing technology, etc. It also provides complete supporting services, mainly including discipline construction services, laboratory personnel training, equipment maintenance, technical support services, sample cold chain distribution, information management software technical support services and laboratory quality control data analysis. 

•The company has participated in the national key research and development program "Cross border service integration theory and key technology", "Independent research and development of integrated products for screening and diagnosis of neonatal genetic metabolic diseases" and the national engineering laboratory project. 

•In 2020, SciNova Fund will invest 15 million yuan to coach CITIC Securities.